• Xianghe Capital seed investment Aifei Zhiyao launched PharmAgents2 with Tsinghua University's Institute for AI Industry Research for autonomous drug discovery.
• The system delivered a new-scaffold LpxH inhibitor, AIPher-L1, with experimentally measured enzyme inhibition IC₅₀ of 8.38 μM.
• JAK1 candidate AIPher-J1 matched positive-control inhibition across two signaling pathways at 10 μM; selectivity remains under validation.
• Parallel screening across 2,607 proteins identified a new target for AIPher-X, with binding subsequently confirmed experimentally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xianghe Business Consulting (Beijing) Co Ltd published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.